MEDICINOVA INC (MNOV) — SEC Financial Statements & Analysis

MEDICINOVA INC (MNOV) is a pharmaceutical preparations company, incorporated in DE. MEDICINOVA INC trades on Nasdaq as: MNOV. MEDICINOVA INC (MNOV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, MEDICINOVA INC carries a market cap of $64.97M, a P/E ratio of -6.04x, a P/B ratio of 1.74x, a P/S ratio of 70.58x, an enterprise value of $39.56M, and an EV/EBITDA multiple of -3.34x. On profitability, it posts an operating margin of -1287.41%, a net margin of -1168.20%, a Return on Equity (ROE) of -25.56%, a Return on Assets (ROA) of -23.83%, and a Return on Invested Capital (ROIC) of -96.84%. Per share, it reports EPS of $-0.22, diluted EPS of $-0.22, free cash flow per share of $-0.19, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 583.87% year-over-year, net income growth of -8.97% year-over-year, and EPS growth of -9.29% year-over-year. On the balance sheet, it maintains a current ratio of 8.75x, a quick ratio of 8.58x, working capital of $22.96M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.08, free cash flow of $-9.12M (TTM), and net debt of $-25.42M. Figures sourced from SEC EDGAR.

Market Cap

$64.97M

P/E TTM

-6.04x

EPS TTM

$-0.22

P/B TTM

1.74x

ROE TTM

-25.56%

ROA TTM

-23.83%

Debt To Equity

0.08x

Free Cash Flow TTM

$-9.12M

Net Revenue TTM Growth 1Y

583.87%

Data as of 2026-06-30 · Source: SEC EDGAR